KURA ONCOLOGY, INC. Paid-in-Kind Interest
KURA ONCOLOGY, INC. (KURA) reported Paid-in-Kind Interest of $73.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2023-02-23
- KURA ONCOLOGY, INC. paid-in-kind interest for the quarter ending 2021-12-31 was $0.00.
- KURA ONCOLOGY, INC. paid-in-kind interest for the quarter ending 2021-09-30 was $0.00.
- KURA ONCOLOGY, INC. paid-in-kind interest for fiscal 2022 was $73.00K, a 81.70% decline from fiscal 2021.
- KURA ONCOLOGY, INC. paid-in-kind interest for fiscal 2021 was $399.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2022-12-31 | $73.00K 10-K · filed 2023-02-23 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $399.00K 10-K · filed 2023-02-23 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $399.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $399.00K 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |